Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 33, Issue 4, 2014, Pages 629-638

  Doring M ^a   Blume, O ^a   Haufe, S ^a   Hartmann, U ^a   Kimmig, A ^a   Schwarze, C P ^a   Lang, P ^a   Handgretinger, R ^a   Muller I ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALANINE AMINOTRANSFERASE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ASPARTATE AMINOTRANSFERASE; BICARBONATE; CALCIUM; CASPOFUNGIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; ITRACONAZOLE; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PENICILLIN V; PHOSPHATE; POSACONAZOLE; POTASSIUM; THYMOCYTE ANTIBODY; VORICONAZOLE; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BICARBONATE BLOOD LEVEL; CALCIUM BLOOD LEVEL; CHILD; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERANCE; FEASIBILITY STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBSERVATIONAL STUDY; PHOSPHATE BLOOD LEVEL; PHOTOSENSITIVITY; POTASSIUM BLOOD LEVEL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; SCHOOL CHILD; SKIN MANIFESTATION; SYSTEMIC MYCOSIS; VOMITING; ALLOTRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFANT; ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATIONS; PROCEDURES;

ADMINISTRATION, ORAL; ADOLESCENT; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES;

EID: 84897065789     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-013-1998-2     Document Type: Article

References (38)

1. Steinbach WJ (2010) Invasive aspergillosis in pediatric patients. Curr Med Res Opin 26:1779-1787
2. Zaoutis T (2010) Candidemia in children. Curr Med Res Opin 26:1761-1768
3. Cuenca-Estrella M, Rodríguez-Tudela JL, Mellado E, Martínez-Suárez JV, Monzón A (1998) Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 42:531-533 (Pubitemid 28473016)
4. Espinel-Ingroff A, Canton E, Gibbs D, Wang A (2007) Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole. J Clin Microbiol 45:858-864 (Pubitemid 46427702)
5. Espinel-Ingroff A, Boyle K, Sheehan DJ (2001) In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150:101-115 (Pubitemid 32623880)
6. Potter M, Donnelly JP (2004) The role of itraconazole in preventing and treating systemic fungal infections in immunocompromised patients. Acta Haematol 111:175-180 (Pubitemid 38437673)
7. Glasmacher A, Prentice A, Gorschlüter M, Engelhart S, Hahn C, Djulbegovic B et al (2003) Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 21:4615-4626 (Pubitemid 46594036)
8. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL et al (2003) Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 138:705-713
9. Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW (1999) A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 105:901-911 (Pubitemid 29309095)
10. Vardakas KZ, Michalopoulos A, Falagas ME (2005) Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 131:22-28 (Pubitemid 43899704)
11. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415 (Pubitemid 34851833)
12. Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P et al (2002) Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 21:240-248 (Pubitemid 34214142)
13. Grigull L, Kuehlke O, Beilken A, Sander A, Linderkamp C, Schmid H et al (2007) Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: a pilot study for evaluation of safety and efficacy. Pediatr Transplant 11:261-266 (Pubitemid 46570141)
14. Cesaro S, Strugo L, Alaggio R, Cecchetto G, Rigobello L, Pillon M et al (2003) Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience. Support Care Cancer 11:722-727 (Pubitemid 37432629)
15. Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G et al (2006) Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 50:126-133 (Pubitemid 43042912)
16. Maertens J, Groll AH, Cordonnier C, de la Cámara R, Roilides E, Marchetti O (2011) Treatment and timing in invasive mould disease. J Antimicrob Chemother 66:i37-i43
17. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G et al (2006) Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 42:1398-1403
18. Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C et al (2006) Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 42:1726-1734 (Pubitemid 43839438)
19. Schering Corporation (2008) Prescribing information for Noxafil (posaconazole) oral suspension. Schering Corporation, Kenilworth, NJ
20. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R (2004) Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 48:3543-3551 (Pubitemid 39129357)
21. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M (2004) Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 21:645-653 (Pubitemid 38447146)
22. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348-359 (Pubitemid 46148777)
23. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335-347 (Pubitemid 46148776)
24. Döring M, Müller C, Johann PD, Erbacher A, Kimmig A, Schwarze CP et al (2012) Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis 12:263
25. de Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813-1821
26. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7-14 (Pubitemid 33152659)
27. Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health (2006) Common terminology criteria for adverse events v3.0 (CTCAE). DCTD, NCI, NIH, DHHS, Bethesda, MD. Available online at: http://ctep.cancer.gov/ protocoldevelopment/electronic-applications/docs/ctcaev3.pdf
28. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flückiger U, Frêre P et al (2011) European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3 - 2009 update. Bone Marrow Transplant 46:709-718
29. Cornely OA, Böhme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M et al (2009) Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 94:113-122
30. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al (2009) Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15:1143-1238
31. Lehrnbecher T, Attarbaschi A, Duerken M, Garbino J, Gruhn B, Kontny U et al (2010) Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis 29:1043-1045
32. Cesaro S, Milano GM, Aversa F (2011) Retrospective survey on the off-label use of posaconazole in pediatric hematology patients. Eur J Clin Microbiol Infect Dis 30:595-596
33. Faul F, Erdfelder E, Lang A-G, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175-191
34. Winston DJ, Bartoni K, Territo MC, Schiller GJ (2011) Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 17:507-515
35. Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K et al (2010) Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 95:1762-1768. doi:10.3324/haematol.2009.020073
36. Sánchez-Ortega I, Vázquez L, Montes C, Patiño B, Arnan M, Bermúdez A et al (2012) Effect of posaconazole on cyclosporine blood levels and dose adjustment in allogeneic blood and marrow transplant recipients. Antimicrob Agents Chemother 56:6422-6424. doi:10.1128/AAC.01489-12
37. Mann PA, McNicholas PM, Chau AS, Patel R, Mendrick C, Ullmann AJ et al (2009) Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother 53:5026-5034. doi:10.1128/AAC.01031-09
38. Schmalreck AF, Willinger B, Haase G, Blum G, Lass-Flörl C, Fegeler W et al (2012) Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study. Mycoses 55:e124-e137. doi:10.1111/j.1439-0507.2011.02165.x